Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
14.5(c) 14.58(c) 14.62(c) 14.925(c) 14.425 Last
513 581 683 284 813 851 905 525 520 146 Volume
-1.13% +0.55% +0.27% +2.09% -3.35% Change
More quotes
Financials (EUR)
Sales 2018 324 M
EBIT 2018 57,9 M
Net income 2018 44,0 M
Debt 2018 69,7 M
Yield 2018 -
Sales 2019 367 M
EBIT 2019 62,2 M
Net income 2019 52,3 M
Debt 2019 28,6 M
Yield 2019 -
P/E ratio 2018 48,15
P/E ratio 2019 40,89
EV / Sales2018 6,88x
EV / Sales2019 5,95x
Capitalization 2 157 M
More Financials
Company
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.It operates through the EVT Execute and EVT Innovate segments.The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes... 
Sector
Biotechnology & Medical Research
Calendar
05/08 | 08:50pmPresentation
More about the company
Surperformance© ratings of Evotec AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC AG
04/19EVOTEC : and Bayer Advance Third Endometriosis Programme into Phase I Clinical D..
AQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC : and Bayer Advance Third Endometriosis Programme into Phase I Clinical D..
BU
04/18EVOTEC : And bayer advance third endometriosis programme into phase i clinical d..
EQ
04/16EVOTEC : forms collaboration with Petra Pharma on INDiGO platform
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on EVOTEC AG 
EVOTEC AG - 2017
A good level to buy
BUY
More Strategies
Latest Tweets
04/18Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
04/18Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
04/18Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
04/18Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
04/18Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
More tweets
Qtime:35
News from SeekingAlpha
04/11Petra Pharma teams up with Evotec to develop lead candidate Petra-01 
03/28Evotec AG 2017 Q4 - Results - Earnings Call Slides 
03/28Evotec's (EVOTF) CEO Werner Lanthaler on Q4 2017 Results - Earnings Call Tran.. 
03/28Evotec AG reports FY results 
03/26Evotec launches accelerated drug development service 
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,5 €
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG8.30%2 662
CELLTRION, INC.--.--%33 565
IQVIA HOLDINGS INC0.92%20 671
LONZA GROUP-8.28%18 519
NEKTAR THERAPEUTICS56.92%14 892
INCYTE CORPORATION-25.54%14 841